scholarly journals Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer

Cureus ◽  
2020 ◽  
Author(s):  
Michael Chahin ◽  
Nithya Krishnan ◽  
Trevanne Matthews-Hew ◽  
Jason Hew ◽  
Dat Pham
Keyword(s):  
Ovarian Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Anaplastic Lymphoma ◽  
Anaplastic Lymphoma Kinase Rearrangement

scholarly journals EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer

2020 ◽  
Vol 50 (12) ◽  
pp. 1470-1474
Author(s):  
Beina Hui ◽  
Jingping Zhang ◽  
Xiaobo Shi ◽  
Fangfang Xing ◽  
Yang W Shao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Fusion Gene ◽  
Ovarian Cancer Cells ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Kinase Gene ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

Abstract Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress the growth of ovarian cancer cells and transplantation tumours. Here, we present a patient with metastatic ALK+ high-grade serous ovarian cancer that testing positive for EML4-ALK (microtubule-associated protein-like 4 gene, fused to the anaplastic lymphoma kinase gene), experienced dramatic benefit after administration of the anaplastic lymphoma kinase inhibitor alectinib. This is the first clinical evidence that treatment with alectinib may provide a personalized maximum benefit for patients with high-grade serous ovarian cancer who are positive for EML4-ALK.

Sign in / Sign up

Export Citation Format

Share Document